AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 Trial with AFFITOPE® PD01 in Early Parkinson’s Disease Patients

Written by Petra Hegmann on 27th January 2020. Posted in Client News.

• Previous
• Next